Scarica l'app Stockscreener
24.18
2.97%
-0.74
Pre-mercato:
24.31
0.13
+0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$24.92
Aprire:
$24.95
Volume 24 ore:
9.37M
Relative Volume:
0.84
Capitalizzazione di mercato:
$9.41B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.7698
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-9.47%
1M Prestazione:
-7.04%
6M Prestazione:
-8.37%
1 anno Prestazione:
-35.16%
Intervallo 1D:
$23.77
$25.06
Intervallo di 1 settimana:
$23.77
$26.20
Portata 52W:
$23.04
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.18 | 9.74B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Can Moderna Inc. stock hit record highs again2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Moderna Will Talk to Analysts on Thursday. It Needs to Stop Burning Through Cash. - Barron's
Moderna to complete US mRNA manufacturing network with $140 million investment - Reuters
Moderna to onshore drug production at Norwood facility as part of $140M expansion - The Business Journals
Moderna (MRNA) Expands U.S. Manufacturing with $140M Investment - GuruFocus
Moderna completes end-to-end mRNA manufacturing network in U.S. - Seeking Alpha
Moderna (MRNA) Expands U.S. Manufacturing with New Facility - GuruFocus
Moderna expands US manufacturing with new drug product facility By Investing.com - Investing.com Australia
Moderna expands US manufacturing with onshoring of drug product capabilities - MarketScreener
Moderna expands US manufacturing with new drug product facility - Investing.com
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities - ACCESS Newswire
Moderna (NASDAQ: MRNA) Onshores Product to Complete U.S. mRNA Manufacturing - Stock Titan
KBC Group NV Trims Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Brings Back Drug Product Manufacturing To Home Ground - Stocktwits
Geode Capital Management LLC Buys 1,420,690 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025 - The Derrick
Is Moderna Inc. stock in correction or buying zonePortfolio Gains Report & Fast Entry Momentum Trade Alerts - newser.com
Moderna, Inc. $MRNA Stock Position Lifted by Letko Brosseau & Associates Inc. - MarketBeat
SG Americas Securities LLC Purchases 487,734 Shares of Moderna, Inc. $MRNA - MarketBeat
Berenberg Adjusts Price Target on Moderna to $28 From $30, Maintains Hold Rating - MarketScreener
Financial Gravity Companies Inc. Takes Position in Moderna, Inc. $MRNA - MarketBeat
Candriam S.C.A. Decreases Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Aviva PLC - MarketBeat
How Moderna Inc. stock benefits from tech adoptionOptions Play & Technical Pattern Alert System - newser.com
How strong is Moderna Inc. stock revenue growthJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
How (MRNA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Applying Wyckoff theory to Moderna Inc. stockJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Moderna (MRNA) Tops S&P 500 Short Interest List in October - GuruFocus
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - The Northwest Florida Daily News
Mitsubishi UFJ Asset Management Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock performs during Fed tightening cyclesJuly 2025 Catalysts & Safe Capital Preservation Plans - Fundação Cultural do Pará
Resona Asset Management Co. Ltd. Reduces Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Lohud
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - York Dispatch
Moderna (MRNA) Shareholders Approve Key Proposals at Special Mee - GuruFocus
Moderna Approves Stock Option Exchange Program - TipRanks
Moderna shareholders approve stock option exchange program for employees By Investing.com - Investing.com South Africa
Moderna shareholders approve stock option exchange program for employees - Investing.com
February 2026 Options Now Available For Moderna (MRNA) - Nasdaq
Moderna (MRNA) Stock Surges Amid Partnership Talks and Strong Q3 Results - GuruFocus
What Is Going On With Moderna Stock? - Forbes
5 Insightful Analyst Questions From Moderna's Q3 Earnings Call - Finviz
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire Inc.
Tobam Purchases 55,542 Shares of Moderna, Inc. $MRNA - MarketBeat
5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call - Yahoo Finance
Day 5 of Gains Streak for Moderna Stock with 13% Return (vs. -36% YTD) [11/12/2025] - Trefis
Using Ichimoku Cloud for Moderna Inc. technicalsQuarterly Profit Review & Verified Momentum Watchlists - newser.com
Does Moderna Inc. fit your quant trading modelMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Carisma Therapeutics Inc. SEC 10-Q Report - TradingView
Moderna Inc. recovery potential after sell offCEO Change & High Return Trade Opportunity Guides - newser.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):